Schneider Downs Wealth Management Advisors LP purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, HoldingsChannel.com reports. The fund purchased 8,078 shares of the biopharmaceutical company’s stock, valued at approximately $296,000.

Several other institutional investors and hedge funds have also modified their holdings of the company. Hudson Bay Capital Management LP increased its holdings in shares of Pfizer by 2.2% during the second quarter. Hudson Bay Capital Management LP now owns 230,000 shares of the biopharmaceutical company’s stock valued at $7,521,000 after acquiring an additional 5,000 shares in the last quarter. Argus Investors Counsel Inc. grew its position in Pfizer by 5.3% during the 2nd quarter. Argus Investors Counsel Inc. now owns 108,480 shares of the biopharmaceutical company’s stock worth $3,547,000 after purchasing an additional 5,500 shares during the last quarter. AE Wealth Management LLC increased its stake in Pfizer by 35.0% during the 2nd quarter. AE Wealth Management LLC now owns 376,967 shares of the biopharmaceutical company’s stock valued at $12,327,000 after purchasing an additional 97,799 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Pfizer by 21.2% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 15,704 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,744 shares during the last quarter. Finally, Bank of Nova Scotia Trust Co. lifted its stake in shares of Pfizer by 6.1% during the second quarter. Bank of Nova Scotia Trust Co. now owns 80,342 shares of the biopharmaceutical company’s stock worth $2,627,000 after buying an additional 4,591 shares during the period. Hedge funds and other institutional investors own 69.08% of the company’s stock.

In other Pfizer news, Director Ronald E. Blaylock acquired 13,000 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at $154,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.08% of the company’s stock.

PFE has been the subject of a number of research analyst reports. SVB Leerink raised their target price on Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a research note on Wednesday, July 29th. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $44.00 to $39.00 in a research note on Monday, October 12th. ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Royal Bank of Canada set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Friday. Finally, Berenberg Bank initiated coverage on shares of Pfizer in a report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price objective on the stock. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average target price of $39.64.

PFE opened at $37.95 on Friday. The firm has a fifty day moving average price of $36.59 and a 200 day moving average price of $36.32. Pfizer Inc. has a 1 year low of $27.88 and a 1 year high of $40.97. The stock has a market cap of $210.88 billion, a P/E ratio of 15.06, a P/E/G ratio of 2.91 and a beta of 0.67. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. During the same quarter in the previous year, the company earned $0.80 earnings per share. The firm’s revenue for the quarter was down 11.0% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.89 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a $0.38 dividend. The ex-dividend date is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a yield of 4.01%. Pfizer’s payout ratio is 51.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: The risks of owning bonds

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.